July 17th 2024
During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Behind the FDA Approval: Pemigatinib for R/R Myeloid/Lymphoid Neoplasms
August 30th 2022In the interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the FDA approval of pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. He also discussed the FIGHT-203 trial, and possibilities for pemigatinib in the future.
Read More
Pelabresib and Ruxolitinib Combination Proves Durable in Patients With Myelofibrosis
August 21st 2022Results from the MANIFEST study of pelabresib and ruxolitinib in myelfibrosis are positive. The phase MANIFEST-2 study continue to explored the combination in JAK inhibitor–naïve patients with myelofibrosis.
Read More
Momelotinib Shows Promise for the Future of Treating Myelofibrosis
July 15th 2022In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed phase 3 MOMENTUM study and how it has impacted the clinical trial development of momelotinib for the treatment of patients with myelofibrosis.
Read More
Ruxolitinib Shows Superiority Over BAT in Second-Line, Inadequately-Controlled Polycythemia Vera
June 29th 2022Five-year data from the RESPONSE-2 study combined with prior RESPONSE study results show that there is an option for the roughly 40% of patients with polycythemia vera who become intolerant or resistant to hydroxyurea.
Read More